Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

NCT05219162 ·Status: COMPLETED ·Phase: PHASE4

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NCT03609918 ·Status: COMPLETED

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

NCT05536505 ·Status: RECRUITING ·Phase: PHASE2

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

NCT02381808 ·Status: UNKNOWN

T790M Plasma Testing Methodology Comparison and Clinical Validation

NCT02997501 ·Status: COMPLETED ·Phase: PHASE3

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

NCT02418234 ·Status: COMPLETED

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217 ·Status: UNKNOWN

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NCT04284202 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NCT04552613 ·Status: COMPLETED ·Phase: NA

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

NCT02623257 ·Status: COMPLETED

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

NCT05598528 ·Status: RECRUITING

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

NCT01382992 ·Status: UNKNOWN

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

NCT06422546 ·Status: RECRUITING

Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer

NCT01635400 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

NCT04762459 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264 ·Status: COMPLETED

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

NCT01300429 ·Status: COMPLETED

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

NCT01955421 ·Status: UNKNOWN ·Phase: PHASE2

INHERIT EGFR - Studying Germline EGFR Mutations

NCT01754025 ·Status: ACTIVE_NOT_RECRUITING

Phase I, Study in Chinese NSCLC Patients

NCT02529995 ·Status: COMPLETED ·Phase: PHASE1

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

NCT04207775 ·Status: COMPLETED

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

NCT02618590 ·Status: UNKNOWN